Accessible Search Form           Advanced Search

HHS logo

For Immediate Release: March 1, 2011, 4:00 PM EST

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

For Immediate Release: March 1, 2011, 4:00 PM EST

  • PRINT  |  SHARE

NIH Media Availability: Study Finds Nitric Oxide Does Not Help Sickle Cell Pain Crisis


Inhaling nitric oxide gas does not reduce pain crises or shorten hospital stays in people living with sickle cell disease, according to the results of a new study sponsored by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. 

"Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis," will be published in the March 2 issue of the Journal of the American Medical Association.

Sickle cell disease is an inherited disorder affecting between 70,000 and 100,000 Americans. The disease causes red blood cells, which are normally disc-shaped and pliable, to become misshapen, stiff and sticky.  Severe pain crises occur periodically in people living with sickle cell disease when these sickled red blood cells hinder proper blood flow. 

Nitric oxide dilates and expands blood vessels and enhances blood flow. Levels are lower in persons with sickle cell disease than in those without the disease. Previous trials with smaller numbers of patients had suggested that administration of nitric oxide might shorten sickle cell pain crises. 

This study involved 150 sickle cell disease patients who were hospitalized for severe pain crises. Each participant was given nitric oxide gas or a placebo gas during treatment. Though the nitric oxide was well-tolerated, it failed to improve outcomes. The average length of pain crises among trial participants was 73 hours in the nitric oxide group compared with 65.5 hours in the placebo group, which was not statistically different.  There was also no statistical difference between the two groups in average length of hospital stay or average painkiller usage.

Learn more about this trial at: http://clinicaltrials.gov/ct2/show/NCT00094887

Gregory Kato, M.D., head of NHLBI's Sickle Cell Vascular Disease Section and a co-author on this study, is available to comment on the study's findings and implications for future research.

For more information or to schedule an interview, contact the NHLBI Communications Office at 301-496-4236.

###

The National Heart, Lung, and Blood Institute (NHLBI) is a component of the National Institutes of Health. NHLBI plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at: www.nhlbi.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical, and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

For the Media

NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
Ask for press officer on duty

Related Health Topics

Sickle Cell Anemia

Twitter iconTwitter         Facebook iconFacebook         YouTube iconYouTube        Google+ iconGoogle+